Skip to main content
Banner image
Patient Support and Co-Pay Program

Novartis is proud to support patients through various financial, counseling, and co-pay programs.

Novartis Universal Co-Pay Card

Novartis Oncology Universal Co-Pay Program

Patients may be eligible for immediate co-pay savings on their next prescription of AFINITOR® (everolimus) Tablets and AFINITOR DISPERZ® (everolimus tablets for oral suspension).

 

  • Eligible patients with private insurance may pay $0 per month

  • Novartis will pay the remaining co-pay, up to $15,000 per calendar year, per product*

 

Encourage your patients to find out if they are eligible to enroll in the Novartis Oncology Universal Co-pay Program by visiting Copay.NovartisOncology.com or calling 1-877-577-7756.

*Limitations apply. This offer is only available to patients with private insurance. The program is not available for patients who are enrolled in Medicare, Medicaid, or any other federal or state health care program. Novartis reserves the right to rescind, revoke, or amend this program without notice. For full Terms and Conditions, visit Copay.NovartisOncology.com or call 1-877-577-7756.
Patient Assistance Now Oncology logo

Patient Assistance Now Oncology

Patient Assistance Now Oncology (PANO) is a support center consisting of insurance specialists and case managers who provide access to information regarding an array of services. Consider PANO your first stop for information about Novartis Oncology Patient Support services. Dedicated support specialists help direct callers to the services that best fit their needs.

 

Learn more by visiting HCP.Novartis.com/Access or calling 1-800-282-7630

Important Safety Information 

AFINITOR and AFINITOR DISPERZ are contraindicated in patients with hypersensitivity to everolimus, to other rapamycin derivatives, or to any of the excipients...

Indications

Advanced HR+, HER2-Negative Breast Cancer

AFINITOR is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole...

Click or scroll to see IMPORTANT SAFETY INFORMATION AND INDICATIONS
References: 1. Afinitor. Prescribing information. Novartis Pharmaceuticals Corp. 2. PubMed. Available at: Afinitor - Search Results - PubMed (nih.gov). Accessed March 10, 2022. 3. Clinicaltrials.gov. Available at Search of: everolimus - Results on Map - ClinicalTrials.gov. Accessed March 10, 2022. 4. Data on file. Afinitor Packs Distributed 2009-2021.